Form 4: Inovio Pharmaceuticals' Chief Scientific Officer, Laurent Humeau, Acquires Shares and Options

Laurent Humeau, Chief Scientific Officer of Inovio Pharmaceuticals, reports the acquisition of restricted stock units and stock options.

Summary

• Laurent Humeau, the Chief Scientific Officer of Inovio Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On May 20, 2025, Humeau acquired 18,081 restricted stock units (RSUs) and 22,419 common stock options.
• The RSUs vest in three equal installments of 6,027 shares on May 20, 2026, May 20, 2027, and May 20, 2028.
• The stock options vest in two installments: 11,210 shares on May 20, 2027, and 11,209 shares on May 20, 2028.
• The exercise price for the options is $2.13.
• Following these transactions, Humeau directly owns 18,081 RSUs and 22,419 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating standard compensation practices. The acquisition of shares and options by an executive is generally viewed as a positive sign, but it's not a major event.

Positives

• The acquisition of RSUs and stock options by a key executive like the Chief Scientific Officer can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The acquisition of equity by a key executive could positively influence shareholder sentiment.

Key Dates

Keywords

Inovio Pharmaceuticals, Laurent Humeau, Form 4, Beneficial Ownership, Restricted Stock Units, Stock Options, INO